Merck & Co., Inc. (MRK) CEO Ken Frazier on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/04/21
Merck Topples On 'Disappointing Quarter' As CEO Kenneth Frazier Steps DownInvestors Business Daily • 02/04/21
Merck misses profit expectations but beats on revenue, provides upbeat outlookMarket Watch • 02/04/21
Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive ChairmanBusiness Wire • 02/04/21
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin LymphomaBusiness Wire • 02/01/21
Week 5 MDA Breakout Stocks - February 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 02/01/21
Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week24/7 Wall Street • 01/31/21
Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung CancerBusiness Wire • 01/30/21